| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Eupraxia Pharmaceuticals Inc.$6.68
-0.23 (-3.33%)
D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
436.67 M
EPS
-1.01
P/E Ratio
-
Value Trade
1.88 M
-0.28 %
Week
0.28 %
1 Month
-12.67 %
3 Month
12.7 %
6 Month
154.57 %
5 Year
154.57 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
245.82 K
52 Week Range
3.82 - 9.32
% held by Insiders
20.14 %
% held by Institutions
38.57 %
Enterprise Value
327.58 M
Total Shares
6.78 M
Short %
8.81 %
Float Shares
5.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eupraxia Pharmaceuticals Inc.
145Total events
5Upcoming
43Tier-1 (high impact)
2023 – 2028Coverage
Upcoming catalysts 5
Event history 140
Jul 7, 2026
▲Quarterly UpdateCorporate
Appointment of Robert Bazemore, Amy Pott, and Dr. Helen Thackray to Board of Directors
Jul 7, 2026
▲Management ChangeCorporate
Appointment of Robert Bazemore, Amy Pott, and Dr. Helen Thackray to Board of Directors
Q3 2026
◆Topline ReadoutEP-104GIClinical Data
Top-line data from Phase 2b part of RESOLVE trial expected
eosinophilic esophagitissource ↗
Q3 2026
Jun 3, 2026
◆Oral PresentationPresentation
Eupraxia management to present at Jefferies Global Healthcare Conference
May 6, 2026
▲Oral PresentationEP-104GIPresentation
First release of EoEHSS sub scores data at Digestive Disease Week
eosinophilic esophagitissource ↗
May 5, 2026
◆Poster PresentationEP-104GIPresentation
Poster presentation of EP-104GI data from RESOLVE trial at DDW 2026
eosinophilic esophagitissource ↗
May 5, 2026
▲Oral PresentationEP-104GIPresentation
EREFS data presented at DDW 2026
eosinophilic esophagitissource ↗
May 4, 2026
◆R&D DayEP-104GIPresentation
Virtual investor event at DDW 2026 featuring KOLs and EP-104GI discussion
eosinophilic esophagitissource ↗
May 3, 2026
◆Oral PresentationEP-104GIPresentation
Oral presentation of EP-104GI data from RESOLVE trial at DDW 2026
eosinophilic esophagitissource ↗
May 1, 2026
Drug Pipeline Intelligence
D26
Pipeline Score $35M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankEupraxia Pharmaceuticals Inc. faces pipeline headwinds (26/100), with $147M risk-adjusted pipeline value, led by EP-104IAR in Osteoarthritis, Knee (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EP-104IAR Small molecule | Osteoarthritis, Knee | Phase 2 | NCT02609126 | 17% | $144M | COMPLETED | 350 | - | - | Dec 28, 2017 | - | Sep 1, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EP-104GI | eosinophilic esophagitis | Phase 1b/2a | 2026-05-06 | improvement in EoEHSS-i grade and stage was greater than 90% at both 12 and 36 weeks; improvement in EoEHSS-a grade and stage was greater than 83% at both 12 and 36 weeks Read More | Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week Read More | |
EP-104GI | eosinophilic esophagitis | Phase 1b/2a | 2026-05-06 | improvement in EoEHSS-i grade and stage was greater than 90% at both 12 and 36 weeks; improvement in EoEHSS-a grade and stage was greater than 83% at both 12 and 36 weeks Read More | Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week Read More | |
EP-104GI | eosinophilic esophagitis | Phase 1b/2a | 2026-05-06 | improvement in EoEHSS-i grade and stage was greater than 90% at both 12 and 36 weeks; improvement in EoEHSS-a grade and stage was greater than 83% at both 12 and 36 weeks Read More | Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EPRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EPRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EPRX▼ -3.3%today
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
Eupraxia Pharmaceuticals has appointed three industry leaders, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, to its Board of Directors. This move aims to enhance the company's capabilities in drug development and commercialization, particularly for its gastroenterology assets. The appointments come at a crucial time as Eupraxia looks to advance its pipeline and achieve key milestones.
Read more →EPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Eupraxia Pharmaceuticals announced the successful results of its Annual General Meeting held on June 18, 2026. All seven board nominees proposed by management were elected, and KPMG LLP was re-appointed as the company's auditor. The meeting's outcomes reflect shareholder confidence in the company's direction and governance.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals Inc. will hold its Annual General Meeting on June 18, 2026, in a virtual-only format. Shareholders are encouraged to participate via live webcast, where they can ask questions and vote online. The notice includes guidelines on proxy voting and the process for attending the meeting. Registered shareholders must take note of the voting process outlined in the Management Information Circular to ensure their participation.
Read more →EPRXEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Eupraxia Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company focuses on innovative drug delivery systems using its Diffusphere™ technology. Currently, Eupraxia is advancing its clinical trials, including EP-104GI for EoE and EP-104IAR for knee osteoarthritis pain, which has shown positive results in earlier trials.
Read more →EPRXEupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals reported strong financial results for Q1 2026, highlighting a robust response from the highest dose cohort of EP-104GI in its clinical trials. The company successfully completed a $63.2 million public offering, ensuring funding for ongoing and future clinical programs. Despite a net loss increase, Eupraxia remains well-capitalized into 2028, with over $140 million in cash.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 (Unaudited and Expressed in U.S. Dollars)
Eupraxia Pharmaceuticals Inc. announced its consolidated financial results for the three-month period ending March 31, 2026. The company experienced a net loss of $12.65 million, which is an increase from the $6.77 million loss reported in the same period of the previous year. Their total assets rose significantly, but the company's total liabilities and consolidated deficit also increased, raising concerns about their financial stability. The balance sheet reflects an ongoing trend of increasing losses alongside a reduction in cash reserves.
Read more →EPRXEupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals has released promising sub score data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE). The data, presented at Digestive Disease Week, indicates significant improvements in both inflammation and fibrosis in patients. The highest dose cohorts showed the most substantial benefits, suggesting potential for effective treatment in EoE patients.
Read more →EPRXEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Eupraxia Pharmaceuticals presented promising EREFS data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis at the Digestive Disease Week conference. The data demonstrated a strong correlation between the number of injections and improvements in esophageal inflammation and fibrosis. Notably, patients receiving 20 injections showed a significant reduction in EREFS scores, indicating potential efficacy of the treatment.
Read more →EPRXEupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding Dr. Mark Kowalski. Dr. Tambiah brings over 18 years of experience in clinical development and regulatory strategy. His appointment comes at a crucial time as the company advances its EP-104GI program for Eosinophilic Esophagitis, aiming to expand its gastroenterology pipeline.
Read more →EPRXEupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Eupraxia Pharmaceuticals announced its participation in the Digestive Disease Week Annual Meeting, where it will present four abstracts related to its EP-104GI treatment for eosinophilic esophagitis. The presentations will highlight findings from the Phase 1b/2 RESOLVE trial, showcasing improvements in histological features and inflammation. Additionally, the company will host a virtual investor event featuring key opinion leaders discussing esophageal strictures.
Read more →EPRXEupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has reported promising results from the highest dose cohort of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. At 36 weeks, patients showed significant improvements in tissue health and symptom relief, with 66% maintaining clinical remission. The treatment was well tolerated, with no serious adverse events noted.
Read more →EPRXEupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Eupraxia Pharmaceuticals Inc. will present at two upcoming investor conferences, including the Raymond James Biotech Innovation Symposium and the Bloom Burton & Co. Healthcare Investor Conference. The company is focused on its proprietary Diffusphere™ technology for optimized drug delivery, with ongoing clinical trials for treatments targeting eosinophilic esophagitis and knee osteoarthritis. Eupraxia aims to address significant unmet medical needs across various therapeutic areas.
Read more →EPRXEupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has reported encouraging 24-week symptom data from its Phase 1b/2a RESOLVE trial for EP-104GI, targeting eosinophilic esophagitis. Patients in the highest dose cohort experienced a notable average reduction in symptom scores, with a significant percentage achieving clinical remission. The treatment was well tolerated, with no serious adverse events recorded, highlighting its potential as a new therapeutic option.
Read more →EPRXEupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals reported its financial results for Q4 2025, highlighting a net loss of $16.7 million, up from $7.5 million in the previous year. The company achieved significant clinical milestones and anticipates multiple readouts from its ongoing RESOLVE trial. With a strengthened balance sheet, Eupraxia is positioned for growth and plans to expand its clinical programs.
Read more →EPRXEupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals Inc. announced the closure of a public offering that raised approximately US$63.2 million. The funds from this offering will primarily be used to advance the company's EP-104GI for eosinophilic esophagitis and to expand its pipeline into other gastrointestinal indications. The offering included 7,607,145 common shares sold at US$7.00 each, along with additional pre-funded warrants. The company aims to achieve commercial readiness and reach several development milestones with the proceeds.
Read more →EPRXFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Eupraxia Pharmaceuticals Inc. (the " Company ") 201-2067 Cadboro Bay Rd. Victoria, British Columbia Canada, V8R 5G4 Item 2: Date of Material Change
Eupraxia Pharmaceuticals Inc. announced the closure of its public offering of 7,607,145 common shares, generating gross proceeds of about US$63.2 million. The proceeds will primarily support the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials. Additionally, funds will be allocated for further studies in gastrointestinal indications and to strengthen the company's pipeline and corporate infrastructure.
Read more →EPRXEupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
Eupraxia Pharmaceuticals Inc. has announced the pricing of a public offering, which will raise approximately US$55 million through the sale of 6,428,574 common shares at US$7.00 each. The proceeds will primarily be used to further the development of EP-104GI for Eosinophilic Esophagitis and to support ongoing preclinical studies and Phase 2 clinical trials. The offering is expected to close on February 20, 2026, pending standard closing conditions. In addition, the company aims to use part of the funds for research and development of additional pipeline candidates and to bolster its corporate infrastructure.
Read more →EPRXExecution Version EUPRAXIA PHARMACEUTICALS INC. 6,428,574 Common Shares (without par value) Pre-Funded Warrants to Purchase up to 1,428,571 Common Shares Underwriting Agreement
Eupraxia Pharmaceuticals Inc. has announced an agreement to issue 6,428,574 common shares along with pre-funded warrants to purchase an additional 1,428,571 shares. The offering is underwritten by Cantor Fitzgerald & Co. and is part of a broader effort to raise capital through the issuance of Shelf Securities, amounting to up to $200,000,000. This move follows the approval of necessary prospectuses by Canadian regulatory bodies, positioning the company for future growth.
Read more →EPRXEupraxia Pharmaceuticals Announces Proposed Public Offering
Eupraxia Pharmaceuticals Inc. announced a proposed public offering of common shares to raise funds primarily for further development of its drug EP-104GI targeting Eosinophilic Esophagitis. The offering, detailed in a prospectus supplement filed with the SEC, will include an option for underwriters to purchase additional shares. The net proceeds are intended to support ongoing clinical trials, regulatory submissions, and expansion into additional gastrointestinal disease studies. Closing of the offering is subject to customary conditions and approvals from securities exchanges.
Read more →EPRX▲ +19.1%on this news
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Eupraxia Pharmaceuticals reported promising results from its ongoing RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). At week 12, patients receiving the highest dose exhibited significant improvements in tissue health, with a near-complete normalization observed. Furthermore, the majority of patients maintained clinical remission up to 52 weeks after treatment, indicating durability of response. EP-104GI was well tolerated throughout the study, with no serious adverse events reported.
Read more →EPRXEupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals has reported favorable 52-week follow-up data from its Phase 1b/2a RESOLVE trial, indicating that EP-104GI shows long-term durability and symptom improvement in patients with eosinophilic esophagitis (EoE). Notably, 4 out of 6 patients across Cohorts 5 and 6 remain in clinical remission. The trial achieved no Serious Adverse Events, highlighting the treatment's safety profile. The results suggest that EP-104GI could provide a convenient annual therapeutic option for EoE management.
Read more →EPRXEupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Eupraxia Pharmaceuticals reported strong financial results for Q3 2025, highlighting durable responses from its EP-104GI treatment in the RESOLVE trial. The company successfully completed an $80.5 million public offering, ensuring funding for its pipeline through 2028. However, it also noted an increase in net loss and potential risks from tariffs affecting its operations.
Read more →EPRX▼ -10.5%on this newsshared move
EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months ended
Eupraxia Pharmaceuticals Inc. reported its consolidated financial statements for the period ending September 30, 2025, revealing notable changes in its financial standing. The company increased its cash reserves significantly from $33.1 million to $88.96 million and improved its total assets. However, it also reported a substantial net loss of $6.37 million, exacerbating its overall deficit to $152.87 million. These factors indicate mixed performance as the company navigates its operational challenges.
Read more →EPRXEupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals has announced positive results from the highest-dose cohort in the RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The 8mg dose showed a strong efficacy trend without serious adverse events, leading to plans for an expanded Phase 2 study and a Phase 3 program. The company aims to enhance its developmental programs and address the unmet medical needs in EoE.
Read more →EPRXEupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals has successfully closed a public offering of 14,636,363 common shares, raising approximately $80.5 million. The funds will primarily support the development of EP-104GI for eosinophilic esophagitis and other clinical milestones. CEO James Helliwell highlighted the strong investor interest as a validation of their strategy and technology.
Read more →EPRX▼ -14.9%on this newsshared move
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
Eupraxia Pharmaceuticals has announced the pricing of its public offering, selling 12,727,273 common shares at $5.50 each, aiming to raise around $70 million. The offering is set to close on September 24, 2025, pending customary conditions. Funds will primarily be used for advancing clinical trials and product development.
Read more →EPRX▼ -14.9%on this newsshared move
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
Eupraxia Pharmaceuticals has announced a proposed public offering of common shares to support its product pipeline and ongoing clinical trials. The offering will be priced based on market conditions, and the company plans to use the proceeds for research, development, and general corporate purposes. Underwriters will have a 30-day option to purchase additional shares.
Read more →EPRX▲ +11.6%on this newsshared move
Execution Version EUPRAXIA PHARMACEUTICALS INC. 12,727,273 Common Shares (without par value) Underwriting Agreement
Eupraxia Pharmaceuticals Inc. has announced an underwriting agreement for the sale of 12,727,273 common shares. These shares will be sold to underwriters including Cantor Fitzgerald & Co., with an additional option for the underwriters to purchase up to 1,909,090 more shares. The offering is part of a broader strategy to sell up to $200 million worth of various security classes, which has been properly filed with Canadian and U.S. securities regulators, indicating the company's commitment to regulatory compliance.
Read more →EPRXFirst Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Eupraxia Pharmaceuticals announced promising results from the RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE), showing sustained symptom relief at 52 weeks. The treatment may offer a once-a-year therapy option, contrasting with current daily or weekly treatments. The company plans to release more data later this year.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months ended
Eupraxia Pharmaceuticals Inc. has released its consolidated financial statements for the second quarter of 2025. The report reveals a net loss of $15.5 million, an increase from the $12.2 million loss in the prior year. Notably, the company's cash reserves have decreased substantially, marking significant financial strain. Additionally, total liabilities have seen a slight uptick, coupled with an increase in accumulated deficits, potentially raising concerns regarding the company’s financial health and sustainability.
Read more →EPRXEupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Eupraxia Pharmaceuticals has reported its second quarter 2025 financial results, highlighting key developments in its Phase 2b RESOLVE trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE). The first patient has been dosed in the trial, with topline data expected in the latter half of 2026. Positive data from earlier trials reinforces the treatment's potential, though the company faces financial challenges, including increased net loss and reduced cash reserves. Management is also monitoring potential tariff impacts on its operations in North America.
Read more →EPRXEupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia Pharmaceuticals Inc. has announced its participation in several upcoming investor conferences, including the Canaccord Growth Conference and the Citi Biopharma Conference. The company is focused on developing its DiffuSphere technology for localized drug delivery, with ongoing clinical trials for its product candidates. Recent trials have shown promising results, but the company faces regulatory and operational challenges.
Read more →EPRXEupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has initiated the Phase 2b portion of the RESOLVE trial for EP-104GI, an investigational treatment for eosinophilic esophagitis. The trial will enroll at least 60 participants to evaluate the drug's efficacy and safety. Early data from previous cohorts show promising results, and the company is optimistic about the treatment's potential to improve patient outcomes. Topline data is expected in Q3 2026.
Read more →EPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals held its Annual General and Special Meeting on June 2, 2025, where all six board nominees were elected. Shareholders also re-appointed KPMG LLP as auditors and approved the 2025 Omnibus Incentive Plan. The company continues to develop its DiffuSphere™ technology for targeted drug delivery in various therapeutic areas.
Read more →EPRX▼ -6.8%on this news
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
Eupraxia Pharmaceuticals Inc. announced that it will host a virtual key opinion leader (KOL) event on May 9, 2025, to discuss the Phase 1b/2a RESOLVE Study results of EP-104GI for treating eosinophilic esophagitis (EoE). Dr. Evan Dellon will present additional clinical data highlighting the safety and efficacy of EP-104GI, which shows promise in addressing a significant unmet medical need. The event will include a Q&A session, allowing for further engagement on this treatment approach.
Read more →EPRXEupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Eupraxia Pharmaceuticals has reported promising data from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis. The company highlighted sustained positive treatment outcomes nine months post-treatment, supporting their drug's potential. Financial results showed a net loss of $6.8 million in Q1 2025, but management expects sufficient funding to continue operations until Q3 2026. The firm is also assessing risks from potential trade tariffs affecting their operations.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Eupraxia Pharmaceuticals Inc. reported its financial results for the first quarter ending March 31, 2025. The company experienced a net loss of $6.77 million, which is an increase compared to the $6.16 million loss from the previous year. Additionally, cash reserves decreased, impacting overall financial stability. The report highlighted a rise in administrative expenses while showing some improvements in property and equipment valuations.
Read more →EPRXEupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
Eupraxia Pharmaceuticals announced promising findings from its ongoing RESOLVE Phase 1b/2a trial, demonstrating positive treatment outcomes for Eosinophilic Esophagitis (EoE) with EP-104GI. New data reveals sustained or improved symptoms nine months after administration in all patients dosed at 48mg. Improvements in tissue health and eosinophil counts were also recorded. Additional findings from the trial are expected with higher doses by Q3 2025.
Read more →EPRXEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
Eupraxia Pharmaceuticals, a clinical-stage biotechnology company, is set to present at several key conferences in April and May 2025. These events will feature presentations on its innovative treatments for osteoarthritis and eosinophilic esophagitis using its proprietary DiffuSphere technology. Notable presentations include data from ongoing Phase 1b and Phase 2b studies. The company aims to address significant unmet medical needs through its novel drug delivery systems.
Read more →EPRXEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Victoria, B.C.
Eupraxia Pharmaceuticals announced its financial results for Q4 2024, reporting a net loss of $7.5 million, improved from the previous year. The company showcased positive outcomes from its Phase 1b/2a RESOLVE trial for EP-104GI aimed at treating eosinophilic esophagitis. Additionally, Eupraxia secured C$44.5 million in funding, aimed to support its operations into the second half of 2026. However, management is closely tracking potential trade tariffs that could affect its supply chain, particularly since it sources its active pharmaceutical ingredients from the U.S.
Read more →EPRX▲ +10.3%on this news
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Histological scores and symptom scores continue to improve as EP-104GI dose, and area
Eupraxia Pharmaceuticals announced positive data from its ongoing RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE). The trial shows significant improvements in both clinical symptoms and tissue health in participants. The company reported no serious adverse events in the first six cohorts, supporting the safety profile of EP-104GI. Eupraxia plans to explore higher dosing levels and wider esophageal coverage in future trial cohorts.
Read more →EPRXEupraxia Pharmaceuticals Announces CFO Succession - Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role Victoria, B.C.
Eupraxia Pharmaceuticals has announced the appointment of Alex Rothwell as its new CFO, succeeding Bruce Cousins who is retiring. Rothwell, who previously held the CFO position, brings over 25 years of experience in capital markets and investment banking. He is expected to contribute significantly to the company's growth, particularly as Eupraxia continues to advance its programs, especially EP-104GI for Eosinophilic Esophagitis and EP-104IAR for knee osteoarthritis. The transition is aimed at ensuring a smooth continuation of leadership as the company focuses on its strategic initiatives.
Read more →EPRX▲ +10.4%on this news
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months DiffuSphere is designed to enable precise drug delivery at therapeutic dose lev
Eupraxia Pharmaceuticals has released new pharmacokinetic data for its DiffuSphere technology, which enables targeted drug delivery with a sustained release profile exceeding six months. The data demonstrate the technology's effectiveness in treating eosinophilic esophagitis and knee osteoarthritis, showing improved patient outcomes and minimized systemic exposure. The unique microsphere design encapsulates drugs in a polymer shell, ensuring high local concentrations and reduced side effects. With encouraging results from clinical trials, Eupraxia is optimistic about the potential of DiffuSphere across various applications.
Read more →EPRX▲ +8%on this news· ran to +24% by day 3shared move
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed" , on
Eupraxia Pharmaceuticals announced that CEO Dr. James Helliwell will present at a webinar focusing on Eosinophilic Esophagitis, an increasingly recognized digestive disorder. Scheduled for November 15, 2024, the event will aim to address the challenges of diagnosing this condition. Eupraxia is actively developing treatments for EoE, leveraging its specialized drug delivery technology. The company previously reported positive results from its clinical trials, signifying its commitment to addressing unmet medical needs in gastrointestinal disorders.
Read more →EPRXEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced its participation in the American College of Rheumatology Convergence 2024 Annual Meeting, scheduled for November 14-19, 2024, in Washington, D.C. The company will present data on its product, EP-104IAR, which focuses on pain management for patients with osteoarthritis of the knee. Using its proprietary DiffuSphere technology, Eupraxia aims to improve local drug delivery and treatment efficacy. This presentation at a prominent rheumatology event highlights Eupraxia's commitment to addressing significant unmet medical needs.
Read more →EPRXEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis One of three patients in Cohort 5 achieved complete histological remis
Eupraxia Pharmaceuticals announced positive data from the fifth cohort of its RESOLVE Phase 1b/2a trial, which evaluates EP-104GI for treating eosinophilic esophagitis (EoE). The new results indicate that 12 injections of EP-104GI led to improved efficacy and safety outcomes, with no reported adverse events. Additionally, higher doses yielded better patient responses, including increased histological remission rates, suggesting the treatment's potential effectiveness. The trial continues to progress, with plans for further data disclosure in the future.
Read more →EPRX▲ +24%on this news· ran to +39% by day 1
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million Victoria, B.C.
Eupraxia Pharmaceuticals has successfully closed a non-brokered private placement, raising C$44.5 million from the issuance of 8,905,638 Series 1 Preferred Shares. The company plans to allocate the net proceeds towards funding clinical trials for its treatment candidate EP104GI and initiating new research programs. Additionally, Mr. Joseph Freedman, a seasoned investor and corporate director, has been appointed to the board as part of the company's strategic developments.
Read more →EPRXEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 Victoria, B.C.
Eupraxia Pharmaceuticals Inc. is set to present two posters at the American College of Gastroenterology Annual Scientific Meeting 2024 in Philadelphia. The posters will include research on EP-104GI, an extended-release formulation of Fluticasone for Eosinophilic Esophagitis. One of the posters received a Presidential Award, while the other was recognized as an ‘Abstract of Interest’. Both presentations aim to showcase Eupraxia's innovative DiffuSphere technology and its implications for drug delivery.
Read more →EPRXLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis Publication of Eupraxia's Phase 2b data in Lancet Rheumatology , a distinguished and respected j
Eupraxia Pharmaceuticals announced the publication of its Phase 2b trial data for EP-104IAR in the Lancet Rheumatology journal. The study demonstrated that EP-104IAR provided significant pain relief for knee osteoarthritis patients, with minimal adverse changes in glucose and cortisol levels. The trial indicated statistically significant improvements in various endpoints, suggesting strong efficacy for the drug. The positive results have heightened the product's profile and potential as a best-in-class therapy in the market.
Read more →EPRXEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced that it will present a poster at the United European Gastroenterology Week 2024, taking place in Vienna, Austria. The poster will highlight results from the RESOLVE trial, which focuses on its drug candidate EP-104GI for eosinophilic esophagitis. This clinical-stage biotechnology company aims to improve drug delivery through its proprietary DiffuSphere technology. The presentation is part of a broader effort to showcase advancements in gastroenterology research and contribute valuable data to the field.
Read more →EPRXEupraxia Pharmaceuticals Strengthens Senior Management Team Victoria, B.C.
Eupraxia Pharmaceuticals has announced the appointments of Amanda Malone as Chief Operating and Scientific Officer and Rahul Sarugaser as Executive Vice President of Corporate Development. These changes aim to strengthen the company's leadership as it advances its DiffuSphere technology in clinical settings. Dr. Malone, a co-founder of Eupraxia, has an extensive background in R&D, while Dr. Sarugaser brings significant capital markets and healthcare experience. The company is focused on developing innovative drug delivery systems to address unmet medical needs.
Read more →EPRXEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases Victoria, B.C.
Eupraxia Pharmaceuticals will present at the 20th International Symposium on Digestive Endoscopy World Congress for Esophageal Diseases in Edinburgh, Scotland, from September 22-24, 2024. They will showcase a poster detailing initial results from the RESOLVE Phase 1b study of their drug EP-104GI aimed at treating eosinophilic esophagitis. This presentation emphasizes the company's commitment to addressing unmet medical needs in gastrointestinal therapy through innovative drug delivery technology.
Read more →EPRXEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the fir
Eupraxia Pharmaceuticals announced positive data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The latest results from the trial's fourth cohort demonstrated consistent improvements in patient-reported outcomes. CEO Dr. James Helliwell expressed optimism regarding the efficacy and safety of EP-104GI, anticipating further positive trends as the trial progresses. The trial aims to assess the drug's dose-response relationship, with results expected from additional cohorts in the near future.
Read more →EPRX▼ -5.8%on this news
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26 th Annual Global Investment Conference Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York, NY. The presentation will highlight Eupraxia's proprietary DiffuSphere technology aimed at enhancing drug delivery for unmet medical needs. The company is currently advancing its clinical programs, including EP-104GI for eosinophilic esophagitis, and recently completed a successful Phase 2b trial for EP-104IAR. This engagement reflects Eupraxia's dedication to addressing critical therapeutic areas.
Read more →EPRX▼ -10.1%on this newsshared move
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility The Company also provides an update on the Silicon Valley Bank convertible debt facility Including the new C$12 million convertible debt facil
Eupraxia Pharmaceuticals announced a new C$12 million convertible debt facility to enhance its funding options, secured from supportive investors. This move is expected to stabilize its capital structure as the company advances its clinical programs in eosinophilic esophagitis and osteoarthritis. The existing facility with Silicon Valley Bank is in the process of being fully settled, which may impact cash reserves. Despite this, Eupraxia anticipates having sufficient funds to support operations until mid-2025.
Read more →EPRXEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced that its Chief Operating and Scientific Officer, Dr. Amanda Malone, will present at the Controlled Release Society 2024 Annual Meeting and Expo in Bologna, Italy. The presentation will focus on EP-104, a novel microparticle formulation designed for extended-release of fluticasone propionate. Eupraxia aims to address significant unmet medical needs with its DiffuSphere technology, and it has promising ongoing clinical trials for treatments related to eosinophilic esophagitis and osteoarthritis. However, the company faces challenges including reliance on third-party supplies and regulatory hurdles.
Read more →EPRXEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on
Eupraxia Pharmaceuticals has announced that its CEO, Dr. James Helliwell, will participate in an upcoming Tribe Public Webinar titled 'Exploring the Rapid Rise of Osteoarthritis' set for July 9, 2024. This event aims to enhance awareness about osteoarthritis and will feature a Q&A session for participants. Eupraxia is thereby leveraging this platform to discuss its clinical advancements and proprietary technology, particularly its DiffuSphere system designed for improved drug delivery. This initiative underscores the company's commitment to addressing significant unmet medical needs in therapeutic areas.
Read more →EPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced the results from its Annual General and Special Meeting of Shareholders held on June 6, 2024. All six candidates nominated for the board of directors were elected with a significant majority. Additionally, shareholders approved a range of business items, including appointing KPMG LLP as the company's auditor and authorizing changes to the stock option plan. The meeting's successful outcomes reflect strong support for the company's leadership and objectives moving forward.
Read more →EPRXEupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 Victoria, B.C.
Eupraxia Pharmaceuticals announced that it will present data from its Phase 2 SPRINGBOARD study on EP-104IAR for knee osteoarthritis at the EULAR European Congress of Rheumatology 2024. The presentation is scheduled for June 14, 2024, in Vienna, Austria, and follows positive results from the trial, which met its primary endpoint and most secondary endpoints. The use of Eupraxia's proprietary DiffuSphere technology aims to optimize drug delivery, addressing significant unmet needs in the therapeutic area of osteoarthritis.
Read more →EPRXEupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eight of nine patients responding to the treatment, plus the encouraging safety data observe
Eupraxia Pharmaceuticals has announced the expansion of its Phase 1b/2a RESOLVE trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE). This decision follows positive initial data showing patient responsiveness and safety from the treatment. Regulatory bodies in Australia and Canada have approved the protocol amendment, allowing for higher doses and an increased participant pool. With the encouraging results, the company aims for a potential registration trial in 2025.
Read more →EPRXEupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on
Eupraxia Pharmaceuticals is set to host a virtual key opinion leader (KOL) event on May 29, 2024, to discuss its EP-104GI clinical development program for Eosinophilic Esophagitis (EoE). The event will feature Dr. Evan S. Dellon from the University of North Carolina, focusing on the unmet medical needs surrounding EoE and insights from the Phase 1b/2a RESOLVE clinical trial. EP-104GI utilizes Eupraxia's proprietary DiffuSphere technology to potentially enhance drug delivery to esophageal tissue. A live Q&A session will follow the presentation to address further questions from participants.
Read more →EPRXEupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Trial's first and second cohorts maintaining signs of potential efficacy out to 24
Eupraxia Pharmaceuticals has announced encouraging data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis. The new results indicate sustained efficacy signals and safety across multiple cohorts. Specifically, the trial showed significant improvements in symptom scores and reductions in eosinophil counts. The company plans to continue sharing additional data periodically, which may enhance the understanding of EP-104GI's potential as a treatment option.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF EUPRAXIA PHARMACEUTICALS INC. TO BE HELD ON JUNE 6, 2024 MANAGEMENT INFORMATION CIRCULAR DATED: MAY 1, 2024 EUPRAXIA PHARMACEU
Eupraxia Pharmaceuticals Inc. has announced its annual general and special meeting of shareholders scheduled for June 6, 2024. The meeting will be conducted in a virtual-only format, allowing registered shareholders to participate online. Shareholders must ensure they are registered to vote, as non-registered shareholders will only be allowed to attend as guests without voting rights. Detailed instructions for voting and proxy nominations are provided in the accompanying management information circular.
Read more →EPRXEupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 Victoria, B.C. - May 14 , 2
Eupraxia Pharmaceuticals has announced that it will present initial results from its ongoing Phase 1b study of EP-104GI, aimed at treating eosinophilic esophagitis, at the upcoming Digestive Disease Week Annual Meeting 2024. The presentation will take place in Washington, D.C. from May 18-21, 2024. The Phase 1b/2a study represents a significant step for Eupraxia as it expands its pipeline into gastrointestinal diseases following positive outcomes in previous trials for pain management in osteoarthritis. The results of the study will also be made publicly available on their website after the presentation.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three Months ended
Eupraxia Pharmaceuticals Inc. released its consolidated financial statements for the three months ending March 31, 2024. The company reported a significant increase in cash reserves, with total current assets reaching approximately $36.2 million. However, net losses expanded to $6.16 million compared to $3.96 million during the same period last year, leading to a growing deficit. The company's operational and research expenses indicate a continued investment in development, but financial pressures remain apparent due to rising costs.
Read more →EPRXEupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board - Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program - Victoria, B.C.
Eupraxia Pharmaceuticals has formed a Clinical Advisory Board to advance its eosinophilic esophagitis (EoE) clinical program, particularly focusing on the drug EP-104GI, currently in Phase 1b/2a trials. The board comprises renowned gastroenterology specialists who will provide strategic insights and recommendations for the program's development. Eupraxia's technology promises to optimize drug delivery specifically to the esophagus, aiming to address the significant unmet needs of EoE patients. The move signals potential advancements in therapeutic options for this underserved condition.
Read more →EPRX▼ -6.3%on this news
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 Victoria, B.C.
Eupraxia Pharmaceuticals has announced that it will present two abstracts at the Osteoarthritis Research Society International World Congress 2024, taking place in Vienna from April 18-21, 2024. The presentations will focus on the company's treatment candidate EP-104IAR for knee osteoarthritis, which recently demonstrated significant efficacy in the Phase 2b SPRINGBOARD trial. The results indicated a clinically meaningful impact on pain, and the technology underpinning their approach, Diffusphere, aims to optimize drug delivery. Eupraxia is focused on addressing significant unmet medical needs in osteoarthritis treatment.
Read more →EPRXEupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced that its senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16th in Toronto. The presentation will be led by CEO Dr. James Helliwell, who will also participate in investor meetings at the conference. Eupraxia continues to focus on its proprietary Diffusphere technology aimed at improving drug delivery for medical needs, building on recent successes in clinical trials for its lead candidate, EP-104IAR, for osteoarthritis pain.
Read more →EPRXFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Eupraxia Pharmaceuticals Inc. (the Company ) 201-2067 Cadboro Bay Rd. Victoria, British Columbia Canada, V8R 5G4 Item 2: Date of Material Change
Eupraxia Pharmaceuticals Inc. announced on April 5, 2024, that its common shares will begin trading on the Nasdaq Capital Market under the ticker symbol EPRX. This move is aimed at increasing the company's market presence and visibility. The shares will continue to be listed on the Toronto Stock Exchange under the same ticker. The news release was disseminated through Globe Newswire.
Read more →EPRXEupraxia Pharmaceuticals to Begin Trading on Nasdaq on
Eupraxia Pharmaceuticals Inc. has announced that its common shares have been approved for listing on the Nasdaq Capital Market, with trading expected to begin on April 5, 2024. The company, based in Victoria, B.C., focuses on developing locally delivered, extended-release products targeting areas of significant medical need, utilizing its proprietary Diffusphere technology. Eupraxia's lead candidate, EP-104IAR, has shown positive results in a Phase 2b clinical trial for osteoarthritis pain and is also venturing into gastrointestinal disease with ongoing trials. The company will maintain its presence on the Toronto Stock Exchange with the ticker symbol EPRX.
Read more →EPRXEupraxia Pharmaceuticals Begins Trading on Nasdaq Today Victoria, B.C.
Eupraxia Pharmaceuticals Inc. announced the commencement of trading on the Nasdaq Capital Market under the ticker symbol 'EPRX' on April 5, 2024. The clinical-stage biotechnology company focuses on local drug delivery solutions, utilizing its proprietary Diffusphere technology. Eupraxia recently completed a Phase 2b clinical trial for its lead product, EP-104IAR, demonstrating positive results. The company plans to expand further into gastrointestinal disease and other therapeutic areas with significant unmet needs.
Read more →EPRXEupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results Victoria, B.C.
Eupraxia Pharmaceuticals reported its fourth quarter and full-year financial results, noting a net loss of $10.6 million for Q4 and a total loss of $29.0 million for the year 2023. The company's Phase 1b/2a RESOLVE trial for EP-104GI has shown promising results, and Eupraxia has received positive feedback from the FDA regarding their development path for EP-104IAR. Additionally, Eupraxia has successfully conducted a public offering to strengthen its financial resources, which it plans to allocate towards clinical trials and other corporate needs.
Read more →EPRXNOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million VICTORIA, British Columbia
Eupraxia Pharmaceuticals announced the successful closing of an overnight marketed public offering, raising gross proceeds of C$33.9 million. The offering involved the issuance of 8,260,435 common shares at a price of C$4.10 per share. The funds raised will primarily be used to support the company's ongoing research and development activities, as well as other corporate expenses. This move positions Eupraxia for continued advancement in its clinical-stage biotechnology initiatives.
Read more →EPRXEupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
Eupraxia Pharmaceuticals has announced the closing of its overnight marketed public offering, issuing 8,260,435 common shares at a price of C$4.10 per share, resulting in gross proceeds of approximately C$33.9 million. The funds raised will primarily be utilized to support research and development activities, administrative expenses, and other corporate needs. The shares were offered across Canadian provinces, excluding Québec, and were underwritten by Raymond James Ltd. The company aims to leverage these funds to further its clinical-stage biotechnology initiatives.
Read more →EPRXEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia
Eupraxia Pharmaceuticals has announced the pricing of its overnight marketed offering of common shares, raising approximately $30 million by issuing 7,317,000 shares priced at C$4.10 each. The proceeds will primarily support the company's research and development activities, general administrative expenses, and other corporate purposes. The offering is being conducted under an underwriting agreement with Raymond James Ltd. and is expected to close on March 15, 2024, pending customary conditions including approvals from the Toronto Stock Exchange.
Read more →EPRXEupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia
Eupraxia Pharmaceuticals has announced an overnight marketed public offering to raise approximately $30 million through the sale of common shares. The pricing of the offering will be determined at the time of entering into an underwriting agreement with Raymond James Ltd. The company plans to use the proceeds primarily for its research and development activities, general administrative expenses, and other corporate needs. Completion of the offering is contingent upon market conditions and approval from the Toronto Stock Exchange.
Read more →EPRXEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce today that it has priced its previously anno
Read more →EPRXEupraxia Pharmaceuticals Announces Overnight Marketed Offering
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce it has commenced an overnight marketed publi
Read more →Competitive Position
How EPRX ranks across every disease it competes inCompetitive Position is a premium feature
See how EPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial